Correlation between P450 CYP1A1 inducibility, MspI genotype and lung cancer incidence

European Journal of Cancer Part A

Volumn 32, Issue 10, 1996, Pages 1701-1706

  Jacquet, M ^a   Lambert, V ^a   Baudoux, E ^a   Muller, M ^b   Kremers, P ^a   Gielen, J ^a  

^a CHU SART TILMAN   (Belgium)

^b Service de Physiologie du Travail   (Belgium)

Author keywords

CYP1A1; EROD; Inducibility; Lung cancer; Lymphocytes; Polymorphism; Smoking

Indexed keywords

ARTICLE; CANCER INCIDENCE; CONTROLLED STUDY; GENE INDUCTION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; LUNG CANCER; LYMPHOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SMOKING;

EID: 0030249646     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00172-4     Document Type: Article

References (25)

1. 1. Anttila S, Hietanen E, Vainio H, et al. Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients. Int J Cancer 1991, 47, 681-685.
2. 2. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 1982, 42, 5030-5037.
3. 3. McLemore TL, Adelberg S, Liu MC, et al. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Canc Inst 1990, 82, 1333-1339.
4. 4. Dahl AR, Lewis JL. Respiratory tract uptake of inhalants and metabolism of xenobiotics. [Review]. Ann Rev Pharm Toxicol 1993, 33, 383-407.
5. 5. Phillips DH. Fifty years of benzo(a)pyrene. Nature 1983, 303, 468-172.
6. 6. Bartsch H, Castegnaro M, Rojas M, Camus AM, Alexandrov K, Lang M. Expression of pulmonary cytochrome P4501A1 and carcinogen DNA adduct formation in high risk subjects for tobacco-related lung cancer. Toxicol Lett 1992, 64-65 Spec, No: 477-483.
7. 7. Nebert DW, Petersen DD, Puga A. Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics 1991, 1, 68-78.
8. 8. Kellermann G, Shaw CR, Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med 1973, 289, 934-937.
9. 9. Crofts F, Cosma GN, Currie D, Taioli E, Toniolo P, Garte SJ. A novel CYP1A1 gene polymorphism in African-Americans [published erratum appears in Carcinogenesis 1993, 14(12), 2652]. Carcinogenesis 1993, 14, 1729-1731.
10. 10. Kawajiri K, Nakachi K, Imai K, Hayashi S, Watanabe J. Individual differences in lung cancer susceptibility in relation to polymorphisms of P-450IA1 gene and cigarette dose. Int Sympos of the Princess Takamatsu Cancer Research Fund 1990, 21, 55-61.
11. 11. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Letters 1990, 263, 131-133.
12. 12. Wedlund PJ, Kimura S, Gonzalez FJ, Nebert DW. 1462V mutation in the human CYP1A1 gene: lack of correlation with either the Msp I 1.9 kb (M2) allele or CYP1A1 inducibility in a three-generation family of east Mediterranean descent. Pharmacogenetics 1994, 4, 21-26.
13. 13. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem 1991, 110, 407-411.
14. 14. Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 1994, 15, 1785-1790.
15. 15. Drakoulis N, Cascorbi I, Brockmoller J, Gross CR, Roots I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Invest 1994, 72, 240-248.
16. 16. Hayashi S, Watanabe J, Nakachi K, Eguchi H, Gotoh O, Kawajiri K. Interindividual difference in expression of human Ah receptor and related P450 genes. Carcinogenesis 1994, 15, 801-806.
17. 17. Kelsey KT, Wiencke JK, Spitz MR. A race-specific genetic polymorphism in the CYP1A1 gene is not associated with lung cancer in African Americans. Carcinogenesis 1994, 15, 1121-1124.
18. 18. Sugimura H, Suzuki I, Hamada GS, et al. Cytochrome P-450 Ia1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil. Cancer Epidemiol Biomarkers Prevention 1994, 3, 145-148.
19. 19. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H. Point-mutational MspI and Ile-Va1 polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prevention 1992, 1, 485-489.
20. 20. Landi PJ, Bertazzi PA, Shields PG, et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994, 4, 242-246.
21. 21. Kouri RE, Oberdorf J, Slomiany DJ, McKinney CE. A method for detecting aryl hydrocarbon hydroxylase activities in cryopreserved human lymphocytes. Cancer Lett 1981, 14, 29-40.
22. 22. Burke MD, Mayer RT. Ethoxyresorufin: direct fluorimetric assay of a microsomal o-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Met Disp 1974, 2, 583-588.
23. 23. Peterson JA, Ebel RE, O'Keefe DH. Dual-wavelength stopped-flow spectrophotometric measurement of NADPH-cytochrome P-450 reductase. Method Enzymol 1978, 52, 221-226.
24. 24. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning - A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 1982.
25. 25. Anttila S, Hirvonen A, Husgafvel-Pursiainen K, et al. Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histological type of lung cancer. Carcinogenesis 1994, 15, 1133-1135.